PSG
16.3.2021 09:10:12 CET | Business Wire | Press release
Imaweb, a leading independent developer and provider of automotive and dealership digital software solutions in Europe, today announced the acquisition of Stampyt, a leading French provider of remarketing software and other digital solutions for the second-hand vehicle market. Imaweb is backed by funds advised by PSG, a leading growth equity firm that focuses on partnering with middle-market software and technology-enabled service companies.
Founded in 2015, Stampyt’s AI-driven imaging technology enables dealerships and original equipment manufacturers (OEMs) to boost their second-hand vehicle sales by providing them with innovative digital solutions to support aftersales and remarketing activities. In addition to photo and video technology, Stampyt also develops and commercialises a suite of complementary solutions allowing dealers and OEMs to, among others, inspect vehicles remotely (leveraging on proprietary AI image editing capabilities) and to digitally manage documents, based on blockchain technology.
Stampyt’s innovative and scalable technology supports the digitalisation of the overall customer journey for dealerships and OEMs and is complementary to Imaweb’s existing suite of digital software solutions. We believe that Imaweb’s pan-European presence will support the accelerated roll-out of Stampyt’s technology across the continent, building on its existing position as a market leader in the French used car market. Following the transaction, CEO Alexandre Launay will continue to lead the business alongside Stampyt’s other Co-Founders, executing on the company’s mission to digitalise the automotive industry.
“We are delighted to welcome the Stampyt team as part of Imaweb today,“ said Patrick Prajs, CEO, and Julian Ciccale, Co-Founder and Deputy CEO, at Imaweb. “Stampyt’s technology is innovative and additive to our existing automotive software solutions. We believe that our continental scale combined with Stampyt’s product offering will accelerate the digitalisation of the entire customer journey for dealerships and OEMs across Europe.”
Alexandre Launay, CEO and Co-Founder of Stampyt added, “We’ve been looking for the right partner to help accelerate our growth internationally and our shared vision meant Imaweb was the natural choice. We are excited to work with the teams at both Imaweb and PSG as we lead the group’s innovation strategy going forward.”
PSG invested in Imaweb in May 2019, backing the company’s founders to seek to transform the leading automotive CRM solutions provider in Spain into a pan-European player. Since then, Imaweb has grown quickly through a combination of organic growth and strategic M&A, most recently the acquisition of Procar in Germany in January 2021. Today, Imaweb offers a full suite of digital software solutions to dealerships and OEMs across Europe.
Financial terms were not disclosed.
Notes to Editors
Imaweb
Imaweb is a leading developer and distributor of digital solutions for the automotive sector in Europe. The company was formed through the merger of Imaweb, a Spanish company dedicated to developing global customer management solutions for sales, marketing and after-sales, and DATAFIRST-I’Car Systems group, a French software development company for car manufacturers, group distributors and dealers, in 2019. For more information, visit https://www.imaweb.com/ .
Stampyt
Stampyt is a leading developer and provider of technologies and solutions for the automotive industry. Ease of use and automation are the DNA of the tools developed by Stampyt to digitalise the automotive sector. Stampyt now collaborates with some of the world’s largest OEMs as well as many French automotive groups to provide imaging technology for the automotive industry. https://en.stamp.yt
PSG
PSG is a growth equity firm that partners with middle-market software and technology-enabled services companies to help them navigate transformational growth, capitalize on strategic opportunities and build strong teams. Having backed more than 65 companies and facilitated over 275 add-on acquisitions, PSG brings extensive investment experience, deep expertise in software and technology, and a firm commitment to collaborating with management teams. Founded in 2014, PSG operates out of offices in Boston, Kansas City and London*. https://www.psgequity.com/
*Currently, the London team operates via an advisory agreement with Providence Equity LLP.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005435/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse
Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom